Wednesday, 22 May 2019

Drug Discovery News

  • Sanofi withdraws diabetes drug NDA in the US

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 13 Sep, 2013

    Singapore: Global pharmaceutical company, Sanofi has temporarily withdrawn new drug application (NDA) for lixisenatide in the US and plans to resubmit in 2015.Lixisenatide is approved in Eu...Read more

  • Amgen to acquire Onyx for $10 bn cash

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 26 Aug, 2013

    Singapore: Global biopharmaceutical company Amgen plans to acquire all the outstanding shares of Onyx Pharmaceuticals for $125-per-share, totalling to $10.40 billion, in cash. The deal woul...Read more

  • Effient trial by Daiichi, Lilly fails to meet primary endpoint

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 27 Aug, 2012

    Singapore: The TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarct...Read more

  • Astellas Pharma opens office in Singapore

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Dec, 2013

    Singapore: Astellas Pharma, Japan's pharmaceutical giant with net sales of $10.7 billion and net income of $881 million as at March 31, 2013, has opened its office in Singapore. Astellas w...Read more

  • A*STAR, GSK develop medicines for emerging markets

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 09 Apr, 2013

    Singapore: GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (E...Read more

  • Aussie firm gets TGA approval for pancreatic cancer drug

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 18 Mar, 2014

    Singapore: Australian biopharmaceutical company, Specialised Therapeutics Australia (STA), has recieved Therapeutic Goods Administration (TGA) approval for ABRAXANE (nanoparticle albumin-bo...Read more

  • Pharmaxis gets grants for fibrotic research

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 08 Jul, 2013

    Singapore: Australian pharmaceutical company Pharmaxis' research projects conducted in conjunction with the University of Sydney have been awarded funding under the Australian Research Coun...Read more

  • Regenerative Therapy for heart failure enters Ph III Trial

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2013

    Singapore: Belgian biotechnology company Cardio3 BioSciences (C3BS) has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congest...Read more

  • Mesoblast to set up stem cell drug plant in Singapore

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 29 May, 2014

    Singapore: Australian regenerative drug company, Mesoblast, is planning to expand its global manufacturing base and the company is in dialogues with Singapore Economic Development Board (ED...Read more

  • Sanford-Burnham, Daiichi form new alliance

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 26 May, 2014

    Singapore: US based Sanford-Burnham Medical Research Institute and Japan's Daiichi Sankyo have formed a three year discovery and pre-clinical drug development partnership for cardiovascular...Read more

  • Boehringer, Eli Lilly to evaluate Trajenta for type 2 diabetes

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

    Singapore: Boehringer Ingelheim and Eli Lilly have initiated phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albumin...Read more

  • Taiwan firm NCE to get priority review in China

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

    Singapore: Taiwan Liposome Company's multi-mechanistic anti-cancer new chemical entity Lipotecan has been accepted into the "Green Path" program by the Chinese State Food and Drug Administr...Read more

  • Astrazeneca, China university in research deal

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 19 Dec, 2012

    Singapore: AstraZeneca has signed a research collaboration with Fudan University, one of China's leading academic institutions in the area of cardiovascular diseases (CVDs). CVDs are a lead...Read more

  • Phylogica extends collaboration with Janssen Biotech

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 31 Jan, 2013

    Singapore: Phylogica, a leading Australian peptide drug discovery company, has extended its collaboration with Janssen Biotech and its affiliates to discover, develop and commercialize new ...Read more

  • AstraZeneca, BMS gets positive regulatory feedback on Type 2 diabetes drug

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 29 Nov, 2013

    Singapore: Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided AstraZeneca and Bristol-Myers Squibb a positive opinion recommending app...Read more

  • Regeneron acquires Sanofi eye care antibodies

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 06 May, 2013

    Singapore: US-based Regeneron Pharmaceuticals has acquired exclusive rights to two families of novel antibodies from Sanofi. Regeneron acquired full rights to antibodies targeting the PDGF ...Read more

  • Teva, Xenon enter $335 mn deal for pain drug

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Dec, 2012

    Singapore: Israel-based Teva Pharmaceutical and Canada-based Xenon Pharmaceuticals have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is curre...Read more

  • Linaclotide phase III trial initiated in China

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 11 Sep, 2013

    Singapore: Ironwood Pharmaceuticals and AstraZeneca Pharmaceuticals have announced the initiation of a phase III clinical trial of linaclotide in China for the treatment of adults with irri...Read more

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls